No, I appreciate that the excerpts you posted are from CYP's corporate governance ann. So it is specific to CYP, but the issue of disclosure under placements and information asymmetry isn't. That CYP corporate governance statement ann is much like clinical trial result anns and an issue I have read you highlight previously - the ann is a summary/generalisation that glosses over some nuance and specifics. In this case it's a general statement of principles, but if you delve into the specifics it contains exceptions. That is a common issue, not just a CYP issue.
CYP's full corporate governance disclosure is here: https://cynata.com/corporate-governance The Continuous Disclosure section alone is a 17 page pdf and notes the exception I posted from the Corporations Regulations in 2.2
- Forums
- ASX - By Stock
- CYP
- Screenshot(s) from Annual Report of 29 Aug 24
Screenshot(s) from Annual Report of 29 Aug 24, page-46
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
(20min delay)
|
|||||
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.74M |
Open | High | Low | Value | Volume |
22.5¢ | 22.5¢ | 22.0¢ | $15.63K | 71K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 20907 | 22.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.0¢ | 30000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 20907 | 0.220 |
2 | 51511 | 0.215 |
3 | 49988 | 0.210 |
1 | 48780 | 0.205 |
3 | 31250 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.230 | 30000 | 2 |
0.235 | 33000 | 1 |
0.240 | 14000 | 2 |
0.250 | 19770 | 2 |
0.265 | 2000 | 1 |
Last trade - 11.55am 11/11/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |
The Watchlist
3DA
AMAERO INTERNATIONAL LTD
Hank Holland, Executive Chairman and CEO
Hank Holland
Executive Chairman and CEO
Previous Video
Next Video
SPONSORED BY The Market Online